Evidence Search
Query across PubMed, Cochrane, Embase, and CINAHL databases
Empagliflozin and Cardiovascular Outcomes in Patients With Heart Failure and Reduced Ejection Fraction: A Multi-Center Randomized Trial
Henriksson T, Vasquez-Molina R, Okafor AE, et al. · European Heart Journal · 2024;45(8):612–624
In 4,744 patients with HFrEF (LVEF ≤40%), empagliflozin 10mg daily reduced the composite primary endpoint of cardiovascular death or heart failure hospitalization by 25% (HR 0.75, 95% CI 0.65–0.86; p<0.001) over a median follow-up of 16 months…
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Updated Meta-Analysis of 12 Randomized Trials
Chen W-L, Abramova NS, Petersen JK, et al. · The Lancet · 2024;403(10421):889–901
Pooled analysis of 12 RCTs (n=28,341) demonstrated that dapagliflozin significantly reduced HF hospitalization (RR 0.71, 95% CI 0.64–0.79) and all-cause mortality (RR 0.88, 95% CI 0.80–0.97) across the full spectrum of LVEF…
Sodium-Glucose Cotransporter 2 Inhibition and Renal Outcomes in Heart Failure: Systematic Review and Trial Sequential Analysis
Nakamura K, de Souza Ferreira AL, Björkström H, et al. · JAMA Cardiology · 2023;8(11):1045–1056
This systematic review of 9 trials (n=15,832) evaluated renal composite outcomes among patients with HF receiving SGLT2 inhibitors. The intervention reduced the risk of sustained eGFR decline ≥40% by 31% (HR 0.69, 95% CI 0.58–0.82)…
Long-Term Safety of Canagliflozin in Elderly Patients With Chronic Heart Failure: Prospective Cohort Analysis
Morales-García F, Lindqvist S, Osei-Bonsu K, et al. · Circulation · 2023;148(14):1102–1113
Among 2,180 patients aged ≥75 years with chronic HF, canagliflozin demonstrated an acceptable safety profile over 24 months. Rates of diabetic ketoacidosis, urinary tract infections, and volume depletion were not significantly elevated…
Paper Screening
Title/abstract screening — 84 of 312 papers reviewed
Effect of Sotagliflozin on Worsening Heart Failure Events in Patients With Diabetes and Recent HF Decompensation
Almeida RG, Fujioka H, van der Berg P, et al. · NEJM · 2024
Multicenter RCT evaluating sotagliflozin initiated before discharge in 1,222 patients with T2DM and acute decompensated HF. Primary endpoint: total HF worsening events at 12 months.
Real-World Prescribing Patterns of SGLT2 Inhibitors in Heart Failure: A National Registry Analysis
Park J-H, Eriksson M, Santos-Oliveira C, et al. · BMJ Open · 2023
Retrospective registry study of 14,560 HF patients examining SGLT2i prescription rates, adherence patterns, and 1-year outcomes across socioeconomic strata.
SGLT2 Inhibitors and Sudden Cardiac Death in Heart Failure: A Systematic Review and Dose-Response Meta-Analysis
Gupta N, Johansson L, Okonkwo IF, et al. · Eur J Heart Fail · 2024
Dose-response meta-analysis of 8 trials (n=21,947) examining SGLT2 inhibitor effects on sudden cardiac death, ventricular arrhythmias, and electrical instability markers.
Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Agonists on Heart Failure Outcomes: Network Meta-Analysis
Hoffman M, Rashidi-Alavijeh A, Takeda Y, et al. · Circulation · 2024
Network meta-analysis of 24 RCTs (n=54,120) comparing SGLT2 inhibitors, GLP-1 agonists, and placebo for composite cardiovascular outcomes in HF populations with and without diabetes.
Study Comparison
Side-by-side characteristics of included trials
| Study | Design | Sample Size | Intervention | Primary Outcome | Effect Size | Risk of Bias | Follow-up |
|---|---|---|---|---|---|---|---|
| Henriksson 2024 Eur Heart J |
RCT | 4,744 | Empagliflozin 10mg vs placebo | CV death or HF hospitalization | HR 0.75 0.65–0.86 |
Low | 16 mo |
| Chen 2024 The Lancet |
MA | 28,341 | Dapagliflozin (various doses) | HF hospitalization | RR 0.71 0.64–0.79 |
Low | — |
| Nakamura 2023 JAMA Cardiol |
SR | 15,832 | SGLT2i (class-level) | Sustained eGFR decline ≥40% | HR 0.69 0.58–0.82 |
Moderate | 24 mo |
| Hoffman 2024 Circulation |
NMA | 54,120 | SGLT2i vs GLP-1 RA vs placebo | Composite CV outcome | HR 0.78 0.71–0.86 |
Low | 18 mo |
| Almeida 2024 NEJM |
RCT | 1,222 | Sotagliflozin vs placebo | Total HF worsening events | RR 0.67 0.55–0.82 |
Low | 12 mo |
Note Synthesis
Extracted findings organized by theme
Mortality Reduction
4 notesConsistent reduction in cardiovascular mortality across all SGLT2 inhibitors (pooled HR 0.86, 95% CI 0.78–0.95). Effect appears independent of baseline diabetes status.
All-cause mortality benefit less consistent — significant in empagliflozin trials (HR 0.83) but not in dapagliflozin-only analyses (HR 0.93, p=0.12). Possible drug-specific effect or power issue.
Sudden cardiac death reduction noted in meta-analysis (HR 0.73, 95% CI 0.55–0.98) — potential anti-arrhythmic mechanism via ketone body utilization and reduced myocardial fibrosis.
Hospitalization Outcomes
3 notesHF hospitalization reduction is the most robust finding across all included studies (class-level RR 0.71). Number needed to treat (NNT) = 21 over 12 months.
Early initiation (pre-discharge) associated with greater hospitalization reduction (Almeida: RR 0.67 vs post-discharge initiation: RR 0.80). Supports "start before discharge" protocols.
Renal Protection
2 notesSGLT2 inhibitors reduce sustained eGFR decline ≥40% by 31% (HR 0.69). The renal protective effect is independent of and additive to cardiovascular benefits.
Safety Profile
2 notesGenital mycotic infections elevated (NNH ≈ 16) across all SGLT2 inhibitors. No significant increase in DKA, amputations, or fractures in HF-specific populations. Volume depletion manageable with dose adjustment.
Citation Organization
41 references across 5 collections
Collections
Henriksson T, Vasquez-Molina R, Okafor AE, et al. Empagliflozin and Cardiovascular Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. Eur Heart J. 2024;45(8):612–624.
Chen W-L, Abramova NS, Petersen JK, et al. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Updated Meta-Analysis. The Lancet. 2024;403(10421):889–901.
Nakamura K, de Souza Ferreira AL, Björkström H, et al. SGLT2 Inhibition and Renal Outcomes in Heart Failure: Systematic Review. JAMA Cardiol. 2023;8(11):1045–1056.
Hoffman M, Rashidi-Alavijeh A, Takeda Y, et al. Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Agonists: Network Meta-Analysis. Circulation. 2024;149(3):201–215.
Almeida RG, Fujioka H, van der Berg P, et al. Effect of Sotagliflozin on Worsening Heart Failure Events. NEJM. 2024;390(4):327–338.
Research Insights
Visual synthesis of evidence quality and effect estimates
Forest Plot — CV Death or HF Hospitalization
Hazard ratios with 95% confidence intervals
PRISMA Flow Diagram
Study selection process
Publication Trend — SGLT2i in Heart Failure
Annual publications indexed in major databases
Keyword Co-occurrence Network
Top research themes and their connections